Ameriprise
LPCN icon

Ameriprise’s Lipocine LPCN Stock Holding History

Ameriprise’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.5K Sell
11,448
-4,656
-29% -$40.6K ﹤0.01% 3964
2025
Q4 		$129K Buy
+16,104
New +$54.2K ﹤0.01% 3979
2023
Q2 		– Sell
-2,588
Closed -$14K – 3963
2023
Q1 		$14K Sell
2,588
-7
-0.3% -$54 ﹤0.01% 3909
2022
Q4 		$18K Buy
2,595
+7
+0.3% +$51 ﹤0.01% 3896
2022
Q3 		$20K Sell
2,588
-1,324
-34% -$14.8K ﹤0.01% 3922
2022
Q2 		$53K Hold
3,912
– – ﹤0.01% 3826
2022
Q1 		$91K Hold
3,912
– – ﹤0.01% 3853
2021
Q4 		$66K Sell
3,912
-19,970
-84% -$371K ﹤0.01% 3897
2021
Q3 		$443K Sell
23,882
-11,883
-33% -$262K ﹤0.01% 3444
2021
Q2 		$851K Sell
35,765
-5,529
-13% -$130K ﹤0.01% 3285
2021
Q1 		$1.06M Sell
41,294
-1,824
-4% -$52.6K ﹤0.01% 3124
2020
Q4 		$997K Sell
43,118
-3,117
-7% -$75K ﹤0.01% 3093
2020
Q3 		$1.11M Sell
46,235
-147
-0.3% -$3.9K ﹤0.01% 2924
2020
Q2 		$994K Sell
46,382
-90
-0.2% -$1.17K ﹤0.01% 2916
2020
Q1 		$269K Buy
46,472
+15,860
+52% +$126K ﹤0.01% 3339
2019
Q4 		$200K Sell
30,612
-4,294
-12% -$110K ﹤0.01% 3579
2019
Q3 		$1.66M Buy
34,906
+1,162
+3% +$46.6K ﹤0.01% 2784
2019
Q2 		$1.12M Sell
33,744
-7,574
-18% -$234K ﹤0.01% 3014
2019
Q1 		$1.62M Buy
41,318
+8,059
+24% +$247K ﹤0.01% 2837
2018
Q4 		$721K Buy
33,259
+18,877
+131% +$438K ﹤0.01% 3069
2018
Q3 		$337K Buy
14,382
+4,882
+51% +$120K ﹤0.01% 3416
2018
Q2 		$210K Buy
9,500
+6
+0.1% +$143 ﹤0.01% 3476
2018
Q1 		$247K Sell
9,494
-59
-0.6% -$1.64K ﹤0.01% 3414
2017
Q4 		$559K Buy
9,553
+59
+0.6% +$3.67K ﹤0.01% 3174
2017
Q3 		$641K Buy
9,494
+341
+4% +$24.7K ﹤0.01% 3132
2017
Q2 		$626K Buy
9,153
+1,412
+18% +$92.1K ﹤0.01% 3148
2017
Q1 		$513K Buy
7,741
+3,859
+99% +$250K ﹤0.01% 3165
2016
Q4 		$243K Sell
3,882
-59
-1% -$3.73K ﹤0.01% 3580
2016
Q3 		$299K Sell
3,941
-6
-0.2% -$372 ﹤0.01% 3401
2016
Q2 		$204K Sell
3,947
-7,700
-66% -$1.19M ﹤0.01% 3537
2016
Q1 		$2.01M Sell
11,647
-922
-7% -$157K ﹤0.01% 2502
2015
Q4 		$2.76M Buy
12,569
+406
+3% +$85.2K ﹤0.01% 2426
2015
Q3 		$2.45M Buy
12,163
+4,763
+64% +$1.1M ﹤0.01% 2500
2015
Q2 		$1.08M Buy
7,400
+2,694
+57% +$334K ﹤0.01% 3103
2015
Q1 		$552K Buy
+4,706
New +$512K ﹤0.01% 3163

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Ameriprise's LPCN Position: Q1 2026 in Review

Ameriprise reduced its Lipocine (LPCN) stake by 29% in Q1 2026, selling an estimated $40.6K and leaving 11,448 shares worth $91.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.

Ameriprise first reported a position in LPCN in Q1 2015 and has held it in 35 quarters since. The position peaked at $2.76M in Q4 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Ameriprise held 11,448 shares of Lipocine worth $91.5K as of Q1 2026.
  • Ameriprise sold 4,656 Lipocine shares in Q1 2026, an estimated $40.6K.
  • Lipocine made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3964 holding.
  • Ameriprise first reported a position in Lipocine in Q1 2015 and has held it in 35 quarters since.
  • Ameriprise's Lipocine position peaked at $2.76M in Q4 2015.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.